{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:25Z","timestamp":1792839625219,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"National Institute for Health Research Birmingham Liver Biomedical Research Unit"},{"name":"Wellcome Trust, the Core Digestive Diseases Charity"},{"name":"PSC"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bpg.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:40:31Z","timestamp":1528936831000},"page":"71-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)"],"prefix":"10.1016","volume":"34-35","author":[{"given":"Ashnila","family":"Janmohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak J.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bpg.2018.06.002_bib1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","article-title":"Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients","volume":"78","author":"Christensen","year":"1980","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib8","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/liv.12434","article-title":"Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study","volume":"34","author":"Boonstra","year":"2014","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29717","article-title":"Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history","volume":"67","author":"Murillo Perez","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"10.1016\/j.bpg.2018.06.002_bib12","first-page":"387","article-title":"Primary biliary cirrhosis. Chronic non-suppurative destructive cholangitis","volume":"46","author":"Rubin","year":"1965","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.002_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1177\/003591576706001205","article-title":"Primary biliary cirrhosis","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc Roy Soc Med"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.002_bib15","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/gut.49.2.276","article-title":"Dutch Multicentre PBCsg. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant","volume":"49","author":"Vleggaar","year":"2001","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.humpath.2012.09.017","article-title":"Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems","volume":"44","author":"Kakuda","year":"2013","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/liv.12620","article-title":"Primary biliary cirrhosis: proposal for a new simple histological scoring system","volume":"35","author":"Wendum","year":"2015","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib20","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.002_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/2010\/431913","article-title":"Autoantibodies and liver disease: uses and abuses","volume":"24","author":"Zeman","year":"2010","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.bpg.2018.06.002_bib25","first-page":"887","article-title":"Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis","volume":"43","author":"Floreani","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"1 Pt 1","key":"10.1016\/j.bpg.2018.06.002_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/hep.1840200120","article-title":"Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits","volume":"20","author":"Murtaugh","year":"1994","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.002_bib27","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","article-title":"Serum bilirubin: a prognostic factor in primary biliary cirrhosis","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib29","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib30","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.002_bib32","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"issue":"8537","key":"10.1016\/j.bpg.2018.06.002_bib34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.bpg.2018.06.002_bib35","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A\u00a0multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib36","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/00365529709000190","article-title":"Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study","volume":"32","author":"Eriksson","year":"1997","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"10.1016\/j.bpg.2018.06.002_bib38","first-page":"2314","article-title":"Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis","volume":"91","author":"Batts","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","author":"Poupon","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.002_bib40","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"issue":"19","key":"10.1016\/j.bpg.2018.06.002_bib41","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib42","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib43","first-page":"759","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib44","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A\u00a0placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid","volume":"108","author":"Vuoristo","year":"1995","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.bpg.2018.06.002_bib45","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2018.06.002_bib46","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib47","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial","volume":"30","author":"Angulo","year":"1999","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.002_bib48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2036.2005.02318.x","article-title":"Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years","volume":"21","author":"Chan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.28128","article-title":"Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists","volume":"63","author":"Trivedi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.002_bib51","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib52","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"11\u201312","key":"10.1016\/j.bpg.2018.06.002_bib53","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/apt.12522","article-title":"Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study","volume":"38","author":"Papastergiou","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib54","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.002_bib55","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.002_bib56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib57","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib58","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A\u00a0prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.002_bib63","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib64","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"A\u00a02-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)","volume":"66","author":"Corpechot","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.002_bib65","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.002_bib67","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.autrev.2016.07.003","article-title":"Novel therapeutics for primary biliary cholangitis: toward a disease-stage-based approach","volume":"15","author":"Mousa","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib68","article-title":"Pharmacological therapies for Primary biliary cholangitis","volume":"32","author":"Harms eaM","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib69","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/j.gastro.2008.07.019","article-title":"Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment","volume":"135","author":"Huet","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib70","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.jhep.2014.07.036","article-title":"AST\/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis","volume":"61","author":"Joshita","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.23","article-title":"Prognostic factors for transplant-free survival and validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid","volume":"8","author":"Cheung","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"10.1016\/j.bpg.2018.06.002_bib72","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1440-1746.2012.07114.x","article-title":"Prevalence and associated factors with esophageal varices in early primary biliary cirrhosis","volume":"27","author":"Ikeda","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jhep.2013.04.010","article-title":"A\u00a0validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score","volume":"59","author":"Patanwala","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.002_bib74","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrgastro.2015.187","article-title":"Primary biliary cirrhosis: renaming primary biliary cirrhosis-clarity or confusion?","volume":"12","author":"Trivedi","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib75","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.002_bib76","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3748\/wjg.v19.i7.1111","article-title":"Risk factors for hepatic decompensation in patients with primary biliary cirrhosis","volume":"19","author":"Shi","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2018.06.002_bib77","article-title":"Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis","author":"Sharma","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"2\u20133","key":"10.1016\/j.bpg.2018.06.002_bib78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12016-015-8483-x","article-title":"Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis","volume":"48","author":"Rong","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"issue":"44","key":"10.1016\/j.bpg.2018.06.002_bib79","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.3748\/wjg.v23.i44.7863","article-title":"Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis","volume":"23","author":"Cheung","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.002_bib80","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","article-title":"Fat-soluble vitamin levels in patients with primary biliary cirrhosis","volume":"96","author":"Phillips","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.002_bib81","first-page":"1356","article-title":"Factors influencing the development of metabolic bone disease in primary biliary cirrhosis","volume":"85","author":"Guanabens","year":"1990","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib82","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression","volume":"35","author":"Menon","year":"2001","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.002_bib83","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/eci.12355","article-title":"Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis","volume":"44","author":"Ruiz-Gaspa","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib84","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib85","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2010.05.026","article-title":"The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up","volume":"53","author":"Jones","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib86","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000360515","article-title":"Pathogenesis of primary biliary cirrhosis and its fatigue","volume":"32","author":"Griffiths","year":"2014","journal-title":"Dig Dis"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib87","first-page":"32","article-title":"Symptoms in PBC \u2013 pathophysiology and management","author":"Jones","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.002_bib88","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s00535-009-0090-2","article-title":"Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population","volume":"44","author":"Kubota","year":"2009","journal-title":"J\u00a0Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib89","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrgastro.2015.12","article-title":"Novel therapeutic targets in primary biliary cirrhosis","volume":"12","author":"Dyson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.002_bib90","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cgh.2013.11.030","article-title":"Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis","volume":"12","author":"Trivedi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2018.06.002_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)31380-5","article-title":"Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis","volume":"62","author":"Cheung","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib92","first-page":"124","article-title":"A\u00a0study of antimitochondrial antibodies in a random population in Estonia","volume":"92","author":"Turchany","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib93","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00535-003-1285-6","article-title":"Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture","volume":"39","author":"Shibata","year":"2004","journal-title":"J\u00a0Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib94","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib95","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.510270303","article-title":"Characterization of antimitochondrial antibodies in health adults","volume":"27","author":"Mattalia","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib96","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib97","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib98","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2\u20133","key":"10.1016\/j.bpg.2018.06.002_bib99","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","article-title":"Extrahepatic autoimmune conditions associated with primary biliary cirrhosis","volume":"48","author":"Floreani","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib100","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00281-014-0439-3","article-title":"Mechanisms of tissue injury in autoimmune liver diseases","volume":"36","author":"Liaskou","year":"2014","journal-title":"Semin Immunopathol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib101","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2036.2012.05223.x","article-title":"Review article: overlap syndromes and autoimmune liver disease","volume":"36","author":"Trivedi","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.002_bib102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis","volume":"44","author":"Poupon","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib103","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.22380","article-title":"Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis","volume":"48","author":"O'Brien","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib104","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cgh.2012.02.010","article-title":"Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis","volume":"10","author":"Dinani","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.002_bib105","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes","volume":"102","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib106","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/jhep.2002.30902","article-title":"Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid","volume":"35","author":"Joshi","year":"2002","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.002_bib107","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1172\/JCI59255","article-title":"Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis","volume":"121","author":"Lee","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bpg.2018.06.002_bib108","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/0016-5085(89)90526-X","article-title":"Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history and influence of survival","volume":"96","author":"Gores","year":"1989","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.002_bib110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cgh.2007.02.031","article-title":"Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis","volume":"5","author":"Levy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.002_bib111","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/MCG.0b013e3181f18c4e","article-title":"Varices in early histological stage primary biliary cirrhosis","volume":"45","author":"Ali","year":"2011","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"11","key":"10.1016\/j.bpg.2018.06.002_bib112","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/01.pas.0000213286.65907.ea","article-title":"Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy","volume":"30","author":"Abraham","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib113","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0168-8278(87)80035-1","article-title":"Portal hypertension in primary biliary cirrhosis. Relationship with histological features","volume":"5","author":"Navasa","year":"1987","journal-title":"J\u00a0Hepatol"},{"issue":"4 Pt 1","key":"10.1016\/j.bpg.2018.06.002_bib114","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0016-5085(92)90771-P","article-title":"Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis","volume":"102","author":"Colina","year":"1992","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.002_bib115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/gut.2004.040832","article-title":"Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?","volume":"54","author":"Bressler","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2018.06.002_bib116","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1016\/S0168-8278(16)00702-9","article-title":"Takikawa H and Japan-PBC consortium. Incidence and predictive factors of decompensating events in primary biliary cholangitis- experiences of 3194 cases in Japan","volume":"64","author":"Tanaka","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.002_bib117","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.22458","article-title":"Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis","volume":"48","author":"Silveira","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib118","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cgh.2006.09.031","article-title":"Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis","volume":"5","author":"Suzuki","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib119","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.510260508","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes","volume":"26","author":"Jones","year":"1997","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.002_bib120","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/hep.23095","article-title":"Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers","volume":"50","author":"Cavazza","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.002_bib121","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/hep.26176","article-title":"Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan","volume":"57","author":"Harada","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.002_bib122","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1478-3231.2009.02160.x","article-title":"Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up","volume":"30","author":"Bjornsson","year":"2010","journal-title":"Liver Int"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691818300386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691818300386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T08:33:55Z","timestamp":1717317235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691818300386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":122,"alternative-id":["S1521691818300386"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2018.06.002","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}